Clinical trial
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
NCT00354367 · UCB Pharma, Industry · Withdrawn
Key facts
| NCT number | NCT00354367 |
|---|---|
| Title | Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas |
| Official title | A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas. |
| Lead sponsor | UCB Pharma, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Certolizumab pegol |
| Enrollment | 0 |
| Start date | Jan 1, 2007 |
| First posted | Jul 20, 2006 |
| Last update posted | May 28, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: